Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCA033989 |
Synonyms | |
Therapy Description |
INCA033989 is a monoclonal antibody targeting mutant CALR, which inhibits downstream signaling and potentially decreases cell proliferation (Blood (2022) 140 (Supplement 1): 14-15). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCA033989 | INCA-033989|INCA 033989 | INCA033989 is a monoclonal antibody targeting mutant CALR, which inhibits downstream signaling and potentially decreases cell proliferation (Blood (2022) 140 (Supplement 1): 14-15). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05936359 | Phase I | INCA033989 INCA033989 + Ruxolitinib | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT06034002 | Phase I | INCA033989 | A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |